Drug Profile

Research Programme: Lead 212 conjugated antibody radiopharmaceuticals - Crescendo Biologics/Orano Med

Alternative Names: 212 PB VH antibodies; ²¹²PB-TAT

Latest Information Update: 17 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orano Med
Developer Crescendo Biologics; Orano Med
Class Antineoplastics; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Jan 2023 Early research in Cancer in United Kingdom (Parenteral) (Orano Med pipeline, January 2023)
12 Jan 2023 Early research in Cancer in USA (Parenteral), prior to January 2023 (Orano Med pipeline, January 2023)
07 Jul 2022 Crescendo Biologics and Orano Med agree to co-develop Lead 212 conjugated antibody radiopharmaceuticals for Cancers

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com